동아ST

We are focusing on the development of global new medicine.

RESEARCH & DEVELOPMENT

Small molecule

Fragment based drug discovery

Fragment-based drug discovery (FBDD) is a screening method using low molecular weight fragments (less than 300 Da).
Compared to high-throughput screening (HTS) which has been widely used in the pharmaceutical industry since the early 2000s,
FBDD can cover a wider chemical space while dramatically saving time and resources.

Small molecule
Fragment hits involve fewer but more optimized interactions (Biochemistry, 2012)

There are now 6 FDA-approved drugs discovered by fragment screening (vemurafenib, venetoclax, pexidartinib, erdafitinib, sotorasib, asciminib) and over 50 molecules in clinical trials.

FBDD requires very sensitive biophysical methods such as SPR, thermal shift assay (TSA) and X-ray crystallography. Based on our deep experience in biophysics, structural biology and computational modeling, Dong-A ST is currently applying FBDD in multiple projects.

Small molecule Small molecule

Targeted Protein Degradation

A proteolysis-targeting chimera (PROTAC) degrader is a chimeric, modular small molecule engineered to induce
the degradation of disease-causing proteins by the ubiquitin-proteasome system

Targeted Protein Degradation
Arvinas presented at the Dana Farber Cancer Institute Targeted Protein Degradation Webinar on Dec 15, 2022
  • E3 E3
    Our platform
    strategy 1

    Novel E3 ligase research & discovery
    Various CRBN / VHL vinders in stock

  • Linker Linker
    Our platform
    strategy 2

    Optimized chemical linker research for permeability Flexible / Rigid / click / linkers in stock

  • Target Target
    Our target selection
    strategy

    Build on our established expertise and capabilities in oncology, immuno-oncology, and neuroscience